All in the Levels—Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal CancerSatya Das, Kristen K. Ciombor, Sarah K Cimino et al.|The Oncologist|2020Cited by 3
Safety considerations with new treatment regimens for anal cancerSarah K Cimino, Cathy Eng, M. Benjamin Hopkins et al.|Expert Opinion on Drug Safety|2021Cited by 3